Botulinum Toxin Type A

ID Pharmacology Interactions References Trials Economics Properties Taxonomy

Targets (2)

Identification

Name

Botulinum Toxin Type A

Accession Number

DB00083 (BTD00092, BIOD00092)

Type

Biotech

Groups

Approved, Investigational

Description

Purified botulinum toxin from Clostridium botulinum, purified from culture via dialysis and acid precipitation.

Protein structure

Protein chemical formula

C₆₇₆₀H₁₀₄₄₇N₁₇₄₃O₂₀₁₀S₃₂

Protein average weight

149322.7 Da

Sequences

>Botulinum Toxin Type A Sequence
MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLN
PPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGG
STIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGY
GSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPN
RVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKA
KSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKV
LNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFT
GLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEE
ITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNG
KKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEA
AMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSG
AVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAK
VNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKA
MININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDK
VNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINI
GSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNN
EYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTIT
NNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELN
EKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPR
GSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQA
GVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAK
LVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL

Download FASTA Format

Synonyms

AbobotulinumtoxinA

BoNT/A

Bontoxilysin A

Botulinum neurotoxin type A precursor

BTX-A

IncobotulinumtoxinA

OnabotulinumtoxinA

External IDs

Not Available

Product Ingredients

Not Available

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Botox	Powder, for solution	100 unit	Intramuscular	Allergan	1992-12-31	Not applicable	Canada
Botox	Injection, powder, lyophilized, for solution	200 [USP'U]/1	Intradermal; Intramuscular	Allergan	2010-01-11	Not applicable	US
Botox	Injection, powder, lyophilized, for solution	100 [USP'U]/1	Intradermal; Intramuscular	Allergan	1989-12-15	Not applicable	US
Botox Cosmetic	Injection, powder, lyophilized, for solution	50 [USP'U]/1	Intramuscular	Allergan	2008-07-15	Not applicable	US
Botox Cosmetic	Powder, for solution	100 unit	Intramuscular	Allergan	2001-05-07	Not applicable	Canada
Botox Cosmetic	Injection, powder, lyophilized, for solution	100 [USP'U]/1	Intramuscular	Allergan	2008-05-20	Not applicable	US
Dysport	Injection, powder, lyophilized, for solution	500 U/1	Intramuscular	Ipsen Biopharmaceuticals, Inc.	2009-11-02	Not applicable	US
Dysport	Injection, powder, lyophilized, for solution	300 U/1	Intramuscular	Ipsen Biopharmaceuticals, Inc.	2009-11-02	Not applicable	US
Dysport	Injection, powder, lyophilized, for solution	300 U/1	Intramuscular	Galderma	2009-11-02	Not applicable	US
Dysport Aesthetic	Powder, for solution	300 unit	Intramuscular	Ipsen Biopharm Limited	2013-02-19	Not applicable	Canada
Dysport Therapeutic	Powder, for solution	500 unit	Intramuscular	Ipsen Biopharm Limited	2017-02-27	Not applicable	Canada
Dysport Therapeutic	Powder, for solution	300 unit	Intramuscular	Ipsen Biopharm Limited	2017-02-27	Not applicable	Canada
Xeomin	Injection, powder, lyophilized, for solution	200 [USP'U]/1	Intramuscular	Merz Pharmaceuticals	2015-11-20	Not applicable	US
Xeomin	Powder, for solution	50 unit	Intramuscular	Merz Pharmaceuticals	2012-07-04	Not applicable	Canada
Xeomin	Injection, powder, lyophilized, for solution	100 [USP'U]/1	Intramuscular	Merz Pharmaceuticals	2010-09-01	Not applicable	US
Xeomin	Injection, powder, lyophilized, for solution	50 [USP'U]/1	Intramuscular	Merz North America, Inc.	2011-08-01	Not applicable	US
Xeomin	Injection, powder, lyophilized, for solution	100 [USP'U]/1	Intramuscular	Merz Pharmaceuticals	2010-09-01	Not applicable	US
Xeomin	Injection, powder, lyophilized, for solution	50 [USP'U]/1	Intramuscular	Merz North America, Inc.	2011-08-01	Not applicable	US
Xeomin	Powder, for solution	100 unit	Intramuscular	Merz Pharmaceuticals	2009-07-21	Not applicable	Canada
Xeomin	Injection, powder, lyophilized, for solution	50 [USP'U]/1	Intramuscular	Merz Pharmaceuticals	2010-09-01	Not applicable	US
Xeomin	Injection, powder, lyophilized, for solution	50 [USP'U]/1	Intramuscular	Merz Pharmaceuticals	2010-09-01	Not applicable	US
Xeomin	Injection, powder, lyophilized, for solution	100 [USP'U]/1	Intramuscular	Merz North America, Inc.	2011-08-01	Not applicable	US
Xeomin Cosmetic	Powder, for solution	100 unit	Intramuscular	Merz Pharmaceuticals	2012-07-05	Not applicable	Canada

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Not Available

Brand mixtures

Not Available

Categories

UNII

E211KPY694

CAS number

93384-43-1

Pharmacology

Indication

For the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and above. Also used cosmetically to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines) as well as for the treatment of excessive underarm sweating.

Structured Indications

Pharmacodynamics

A 150 kDa neurotoxic protein produced from fermentation of Hall strain Clostridium botulinum type A grown in a medium containing casein hydrolysate, glucose and yeast extract. It is purified from the culture solution by dialysis and a series of acid precipitations to a complex consisting of the neurotoxin, and several accessory proteins. Botulinum Toxin Type A is not expected to be present in the peripheral blood at measurable levels following IM or intradermal injection at the recommended doses. The recommended quantities of neurotoxin administered at each treatment session are not expected to result in systemic, overt distant clinical effects, i.e. muscle weakness, in patients without other neuromuscular dysfunction. However, sub-clinical systemic effects have been shown by single-fiber electromyography after IM doses of botulinum toxins appropriate to produce clinically observable local muscle weakness.

Mechanism of action

Botulinum Toxin Type A blocks neuromuscular transmission by binding to acceptor sites on motor or sympathetic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Synaptosomal-associated protein 25	Protein	yes	inhibitor	Human	P60880	details
Rho-related GTP-binding protein RhoB	Protein	unknown	Not Available	Human	P62745	details

Absorption

The chemical complexity of Botulinum Toxin Type A combined with its extreme potency limits the opportunity to study its pharmacokinetic profile in humans. Therefore, no human pharmacokinetic studies have been performed. Botulinum Toxin Type A is injected directly into the target organ, a skeletal muscle. Thus, bioavailability of the intravenous or oral route is not of clinical relevance.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Based on toxicological studies, it has been estimated that the human LD50 by injection is approximately 2800 Units, equivalent to 28 individual vials of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex (100 Units) for a 70 kg adult. When injected intramuscularly, Botulinum Toxin Type A has been shown to be teratogenic or to have embryocidal effects in some animal species.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
Aclarubicin	Aclarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Investigational
Aclidinium	Aclidinium may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Amikacin	Amikacin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved, Vet Approved
Amrubicin	Amrubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved, Investigational
Anisotropine Methylbromide	Anisotropine Methylbromide may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Apramycin	Apramycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Experimental, Vet Approved
Arbekacin	Arbekacin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved
Atracurium besylate	Botulinum Toxin Type A may increase the neuromuscular blocking activities of Atracurium besylate.	Approved
Atropine	Atropine may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved, Vet Approved
Benactyzine	Benactyzine may increase the anticholinergic activities of Botulinum Toxin Type A.	Withdrawn
Benzatropine	Benzatropine may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Biperiden	Biperiden may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Botulinum Toxin Type B	Botulinum Toxin Type A may increase the adverse neuromuscular activities of Botulinum Toxin Type B.	Approved
Chlorphenoxamine	Chlorphenoxamine may increase the anticholinergic activities of Botulinum Toxin Type A.	Withdrawn
Cisatracurium besylate	Botulinum Toxin Type A may increase the neuromuscular blocking activities of Cisatracurium besylate.	Approved
Cyclopentolate	Cyclopentolate may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Darifenacin	Darifenacin may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved, Investigational
Daunorubicin	Daunorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved
Decamethonium	Botulinum Toxin Type A may increase the neuromuscular blocking activities of Decamethonium.	Approved
Desloratadine	Desloratadine may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved, Investigational
Dexetimide	Dexetimide may increase the anticholinergic activities of Botulinum Toxin Type A.	Withdrawn
Dicyclomine	Dicyclomine may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Domoic Acid	Botulinum Toxin Type A may increase the neuromuscular blocking activities of Domoic Acid.	Experimental
Doxacurium chloride	Botulinum Toxin Type A may increase the neuromuscular blocking activities of Doxacurium chloride.	Approved
Doxorubicin	Doxorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved, Investigational
Epirubicin	Epirubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved
Ethopropazine	Ethopropazine may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Fesoterodine	Fesoterodine may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Framycetin	Framycetin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved
Gallamine Triethiodide	Botulinum Toxin Type A may increase the neuromuscular blocking activities of Gallamine Triethiodide.	Approved
Geneticin	Geneticin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Experimental
Gentamicin	Gentamicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved, Vet Approved
GENTAMICIN C1A	GENTAMICIN C1A may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Experimental
Glycopyrronium	Glycopyrronium may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved, Investigational, Vet Approved
Hexamethonium	Hexamethonium may increase the anticholinergic activities of Botulinum Toxin Type A.	Experimental
Hyoscyamine	Hyoscyamine may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Idarubicin	Idarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved
Ipratropium bromide	Ipratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Kanamycin	Kanamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved, Vet Approved
Mecamylamine	Mecamylamine may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Methantheline	Methantheline may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Metixene	Metixene may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Metocurine	Botulinum Toxin Type A may increase the neuromuscular blocking activities of Metocurine.	Approved
Metocurine Iodide	Botulinum Toxin Type A may increase the neuromuscular blocking activities of Metocurine Iodide.	Withdrawn
Metrizamide	Metrizamide may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved
Mivacurium	Botulinum Toxin Type A may increase the neuromuscular blocking activities of Mivacurium.	Approved
Neamine	Neamine may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Experimental
Neomycin	Neomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved, Vet Approved
Neosaxitoxin	Botulinum Toxin Type A may increase the neuromuscular blocking activities of Neosaxitoxin.	Investigational
Netilmicin	Netilmicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved
Orphenadrine	Orphenadrine may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Oxybutynin	Oxybutynin may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved, Investigational
Oxyphenonium	Oxyphenonium may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Pancuronium	Botulinum Toxin Type A may increase the neuromuscular blocking activities of Pancuronium.	Approved
Paromomycin	Paromomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved, Investigational
Pentolinium	Pentolinium may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Pipecuronium	Botulinum Toxin Type A may increase the neuromuscular blocking activities of Pipecuronium.	Approved
Pirarubicin	Pirarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Investigational
Pirenzepine	Pirenzepine may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Plicamycin	Plicamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved, Withdrawn
Procyclidine	Procyclidine may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Propantheline	Propantheline may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Propiverine	Propiverine may increase the anticholinergic activities of Botulinum Toxin Type A.	Investigational
Puromycin	Puromycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Experimental
Quinidine	Quinidine may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Rapacuronium	Botulinum Toxin Type A may increase the neuromuscular blocking activities of Rapacuronium.	Withdrawn
Ribostamycin	Ribostamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved
Rocuronium	Botulinum Toxin Type A may increase the neuromuscular blocking activities of Rocuronium.	Approved
Scopolamine	Scopolamine may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Scopolamine butylbromide	Scopolamine butylbromide may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved, Vet Approved
Sisomicin	Sisomicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Investigational
Solifenacin	Solifenacin may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
SP1049C	SP1049C may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Investigational
Spectinomycin	Spectinomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved, Vet Approved
Streptomycin	Streptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved, Vet Approved
Streptozocin	Streptozocin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved
Succinylcholine	Botulinum Toxin Type A may increase the neuromuscular blocking activities of Succinylcholine.	Approved
Tiotropium	Tiotropium may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Tobramycin	Tobramycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved, Investigational
Tolterodine	Tolterodine may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved, Investigational
Trihexyphenidyl	Trihexyphenidyl may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Trimethaphan	Trimethaphan may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Tropicamide	Tropicamide may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Trospium	Trospium may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Tubocurarine	Botulinum Toxin Type A may increase the neuromuscular blocking activities of Tubocurarine.	Approved
Umeclidinium	Umeclidinium may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved
Valrubicin	Valrubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Approved
Vecuronium	Botulinum Toxin Type A may increase the neuromuscular blocking activities of Vecuronium.	Approved
Zorubicin	Zorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.	Experimental

Food Interactions

Not Available

References

Synthesis Reference

Not Available

General References

Montecucco C, Molgo J: Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005 Jun;5(3):274-9. [PubMed:15907915 ]
Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22;53(7):1431-8. [PubMed:10534247 ]
Shukla HD, Sharma SK: Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol. 2005;31(1):11-8. [PubMed:15839401 ]
Eisenach JH, Atkinson JL, Fealey RD: Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clin Proc. 2005 May;80(5):657-66. [PubMed:15887434 ]
Schurch B, Corcos J: Botulinum toxin injections for paediatric incontinence. Curr Opin Urol. 2005 Jul;15(4):264-7. [PubMed:15928517 ]

External Links

Resource	Link
UniProt	P10845
Genbank	X52066
PharmGKB	PA164754825
Drug Product Database	17056
RxList	http://www.rxlist.com/cgi/generic/botox.htm
Wikipedia	Botox

ATC Codes

M03AX01 — Botulinum toxin

AHFS Codes

92:00.00

PDB Entries

3BTA

FDA label

Download (115 KB)

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Completed	Treatment	Bladder Pain Syndrome	1
0	Completed	Treatment	Strokes	1
0	Not Yet Recruiting	Treatment	Gummy Smile Due to Hypermobile Upper Lip	1
0	Recruiting	Treatment	Neurocostal neuralgia	1
0	Withdrawn	Diagnostic	Benign Prostatic Hyperplasia (BPH) / Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS) / Malignant Neoplasm of Prostate	1
1	Active Not Recruiting	Treatment	Pruritus	1
1	Completed	Other	Psoriasis Vulgaris	1
1	Completed	Treatment	BMI >30 kg/m2	2
1	Completed	Treatment	Cerebral Palsy (CP) / Spasticity	1
1	Completed	Treatment	Dry Eye Syndromes	1
1	Completed	Treatment	Hyperhidrosis	1
1	Completed	Treatment	Osteoarthritis of the Knees	1
1	Completed	Treatment	Scrotal Pain	1
1	Completed	Treatment	Vaginismus	1
1	Completed	Treatment	Vasculogenic Erectile Dysfunction	1
1	Completed	Treatment	Wound; Abdomen, Abdominal Wall	1
1	Recruiting	Treatment	Botulinum Toxins, Type A / Plantar Fascitis	1
1	Recruiting	Treatment	Cervical Pain / Low Back Pain (LBP)	1
1	Recruiting	Treatment	Depressive State / Parkinson's Disease (PD)	1
1	Recruiting	Treatment	Myofascial Pain Syndromes / Myofascial Trigger Point Pain / Trigger Point Pain, Myofascial	1
1	Unknown Status	Treatment	Bruxism / Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint / Temporomandibular Joint Disorders / Temporomandibular Joint Dysfunction Syndrome	1
1	Unknown Status	Treatment	Thoracic Outlet Syndrome	1
1	Withdrawn	Treatment	Torticollis	1
1, 2	Active Not Recruiting	Treatment	Oral Dystonia / Tardive Dystonia	1
1, 2	Completed	Treatment	Benign Prostatic Hyperplasia (BPH)	1
1, 2	Completed	Treatment	Cervical Dystonia / Refractory Cervicothoracic Myofascial Pain Syndrome (CMPS)	1
1, 2	Completed	Treatment	Cluster Headache	1
1, 2	Completed	Treatment	Detrusor Hyperreflexia / Detrusor Instability / Over Active Bladder	1
1, 2	Completed	Treatment	Migraine Disorders	1
1, 2	Completed	Treatment	Synovitis of osteoarthritis	1
1, 2	Not Yet Recruiting	Treatment	Abnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus / Cervical Dystonia Adults	1
1, 2	Not Yet Recruiting	Treatment	Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer	1
1, 2	Not Yet Recruiting	Treatment	Increased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors / Upper Limb Spasticity Unilaterally in Adults With History of Stroke	1
1, 2	Recruiting	Prevention	Nonvalvular Atrial Fibrillation	1
1, 2	Recruiting	Treatment	Cleft Lip / Cleft Palates / Scarring	1
1, 2	Recruiting	Treatment	Cluster Headache	1
1, 2	Recruiting	Treatment	Headache Disorders / Trigeminal Neuralgia (TN)	1
1, 2	Terminated	Treatment	Empty Nose Syndrome / Rhinitis, Atrophic	1
1, 2	Unknown Status	Treatment	Urge Urinary Incontinence	1
2	Active Not Recruiting	Treatment	Carpal Tunnel Syndrome (CTS)	1
2	Active Not Recruiting	Treatment	Low Anterior Resection Syndrome / Rectal Carcinoma	1
2	Active Not Recruiting	Treatment	Masticatory Muscles, Hypertrophy of	1
2	Active Not Recruiting	Treatment	Obesity, Morbid	1
2	Active Not Recruiting	Treatment	Raynaud's Disease	1
2	Completed	Prevention	Migraines	1
2	Completed	Treatment	Amyotrophic Lateral Sclerosis (ALS) / Sialorrhea	1
2	Completed	Treatment	Anal Fissures	1
2	Completed	Treatment	Benign Prostatic Hyperplasia (BPH)	3
2	Completed	Treatment	Blepharospasm	1
2	Completed	Treatment	Botulinum Toxins, Type A	1
2	Completed	Treatment	Burning Mouth Syndrome	1
2	Completed	Treatment	Cerebral Palsy (CP)	1
2	Completed	Treatment	Cerebral Palsy (CP) / Equine and Equinovarus Foot Deformation / Spastic Paraplegia and Hemiparesis	1
2	Completed	Treatment	Cerebral Palsy (CP) / Muscle Spasticity	1
2	Completed	Treatment	Cervical Dystonia	2
2	Completed	Treatment	Cervicogenic Headaches	1
2	Completed	Treatment	Chronic Pain Syndrome / Prostatitis	1
2	Completed	Treatment	Crows Feet / Facial Wrinkles / Lateral Canthal Lines	3
2	Completed	Treatment	Crows Feet / Lateral Canthal Lines	1
2	Completed	Treatment	Cutaneous Leiomyomas / Hereditary Leiomyomatosis and Renal Cell Cancer	1
2	Completed	Treatment	Dementias / Paratonia	1
2	Completed	Treatment	Depressive State	2
2	Completed	Treatment	Detrusor Muscle Hyperactivity	1
2	Completed	Treatment	Essential Tremor of the Upper Limbs	1
2	Completed	Treatment	Facial Rhytids	1
2	Completed	Treatment	Glabellar Frown Lines	3
2	Completed	Treatment	Hyperhidrosis	1
2	Completed	Treatment	Interstitial Cystitis	1
2	Completed	Treatment	Lacrimation increased	1
2	Completed	Treatment	Lateral Canthal Lines	1
2	Completed	Treatment	Major Depressive Disorder (MDD)	1
2	Completed	Treatment	Motor Neurone Disease / Muscle Spasticity / Strokes	1
2	Completed	Treatment	Muscle Contracture / Muscle Spasticity / Strokes	1
2	Completed	Treatment	Muscle Spasticity / Strokes	2
2	Completed	Treatment	Myofascial Pain Syndromes	2
2	Completed	Treatment	Over Active Bladder	3
2	Completed	Treatment	Over Active Bladder / Urinary Incontinence (UI)	1
2	Completed	Treatment	Pain of the knee	1
2	Completed	Treatment	Parkinson / Tremors	1
2	Completed	Treatment	Postherpetic Neuralgia	1
2	Completed	Treatment	Proctalgia	1
2	Completed	Treatment	Restless Legs Syndrome (RLS)	1
2	Completed	Treatment	Sialorrhea	1
2	Completed	Treatment	Skin Aging	1
2	Completed	Treatment	Stomach Neoplasms	1
2	Completed	Treatment	Thoracic Outlet Syndrome	1
2	Completed	Treatment	Synovitis of osteoarthritis	1
2	Enrolling by Invitation	Prevention	Post-operative Excessive Scarring	1
2	Enrolling by Invitation	Treatment	Scrotal Pain	1
2	Enrolling by Invitation	Treatment	Tremors	1
2	Not Yet Recruiting	Treatment	Temporo-Myofascial Disorder	1
2	Recruiting	Supportive Care	Oesophageal Carcinoma	1
2	Recruiting	Treatment	Atrial Flutter	1
2	Recruiting	Treatment	Benign Prostatic Hyperplasia (BPH) / Lower Urinary Track Symptoms	1
2	Recruiting	Treatment	Bladder Pain Syndrome	1
2	Recruiting	Treatment	Borderline Personality Disorder (BPD)	1
2	Recruiting	Treatment	Cerebral Palsy, Spastic / Pain	1
2	Recruiting	Treatment	Cervical Dystonia	1
2	Recruiting	Treatment	Chronic Diseases / Nasal Polyposis / Rhinitis	1
2	Recruiting	Treatment	Chronic Testicular Pain	1
2	Recruiting	Treatment	Dystonias	1
2	Recruiting	Treatment	Hyperhidrosis	1
2	Recruiting	Treatment	Hypertrophy of Masseter Muscle	1
2	Recruiting	Treatment	Migraine Disorders / Migrainous Headache / Pediatrics	1
2	Recruiting	Treatment	Neuropathic Back Pain / Spinal Cord Injuries (SCI)	1
2	Recruiting	Treatment	Obstructed Defecation Syndrome (ODS)	1
2	Recruiting	Treatment	Parkinson's Disease (PD)	1
2	Recruiting	Treatment	Peyronie's Disease	1
2	Recruiting	Treatment	Post-Operative Pain	1
2	Recruiting	Treatment	Premature Ejaculation	1
2	Recruiting	Treatment	Rotator Cuff Tear Arthropathy	1
2	Recruiting	Treatment	Tremor, Essential	1
2	Recruiting	Treatment	Trigeminal Neuralgia (TN)	1
2	Terminated	Treatment	Acne Vulgaris	1
2	Terminated	Treatment	Allodynia / Pain, Neuropathic	1
2	Terminated	Treatment	Blepharospasm	1
2	Terminated	Treatment	Cerebral Palsy (CP)	1
2	Terminated	Treatment	Habitual Snoring	1
2	Terminated	Treatment	Lower Back Pain	1
2	Terminated	Treatment	Neurogenic Bladder Dysfunction Nos / Spinal Cord Injuries (SCI)	1
2	Terminated	Treatment	New Daily Persistent Headache	1
2	Terminated	Treatment	Over Active Bladder	2
2	Terminated	Treatment	Pain	1
2	Unknown Status	Prevention	Scarring	1
2	Unknown Status	Treatment	Arthritis / Pain	1
2	Unknown Status	Treatment	Epidermolysis Bullosa Simplex	1
2	Unknown Status	Treatment	Hemifacial Spasm	1
2	Unknown Status	Treatment	Rosaceas	1
2	Withdrawn	Treatment	Amyotrophic Lateral Sclerosis (ALS) / Parkinson's Disease (PD)	1
2	Withdrawn	Treatment	Contact Ulcer of Vocal Folds / Granuloma / Granuloma of Vocal Cords / Granuloma, Laryngeal	1
2	Withdrawn	Treatment	Lower Urinary Tract Symptoms (LUTS) / Malignant Neoplasm of Prostate / Radioactive Seed Implantation	1
2	Withdrawn	Treatment	Neuroma	1
2	Withdrawn	Treatment	Over Active Bladder / Urinary Incontinence (UI)	1
2, 3	Completed	Treatment	Benign Prostatic Enlargement (BPE) / Benign Prostatic Hyperplasia (BPH)	1
2, 3	Completed	Treatment	Chronic Plantar Fasciitis	1
2, 3	Completed	Treatment	Fowler's Syndrome / Urinary Retention	1
2, 3	Completed	Treatment	Recalcitrant Alopecia Totalis / Recalcitrant Alopecia Universalis	1
2, 3	Completed	Treatment	Refractory Migraine	1
2, 3	Completed	Treatment	Sialorrhea	1
2, 3	Not Yet Recruiting	Treatment	Base-of-thumb Osteoarthritis	1
2, 3	Recruiting	Prevention	Scarring	1
2, 3	Recruiting	Treatment	Blepharospasm	1
2, 3	Recruiting	Treatment	Crows Feet Lines	1
2, 3	Recruiting	Treatment	Erectile Dysfunction (ED) / Sexual Dysfunctions	1
2, 3	Terminated	Treatment	Primary Focal Hyperhidrosis of the Hands	1
2, 3	Unknown Status	Prevention	Forward Head Posture With Associated Episodic Headache Disorder	1
2, 3	Unknown Status	Treatment	Cerebral Palsy (CP) / Sialorrhea	1
2, 3	Unknown Status	Treatment	Lower Limb Spasticity After Stroke	1
2, 3	Unknown Status	Treatment	Non-relaxing Puborectalis Syndrome	1
2, 3	Unknown Status	Treatment	Over Active Bladder	1
3	Active Not Recruiting	Treatment	Cerebral Palsy (CP) / Spasticity	1
3	Active Not Recruiting	Treatment	Glabellar Lines	1
3	Completed	Not Available	Aging	1
3	Completed	Supportive Care	Stroke With Hemiparesis	1
3	Completed	Treatment	Allodynia / Headaches	1
3	Completed	Treatment	Bilateral Blepharospasm (BEB)	1
3	Completed	Treatment	Blepharospasm	2
3	Completed	Treatment	Canthal Lines	1
3	Completed	Treatment	Cerebral Palsy (CP) / Children / Muscle Spasticity	2
3	Completed	Treatment	Cerebrovascular Accidents	3
3	Completed	Treatment	Cervical Dystonia	5
3	Completed	Treatment	Chronic Low-back Pain	1
3	Completed	Treatment	Chronic Troublesome Sialorrhea / Parkinson's Disease (PD) / Post-stroke / Traumatic Brain Injury (TBI)	1
3	Completed	Treatment	Crow's Feet Lines / Facial Rhytides / Glabellar Lines	2
3	Completed	Treatment	Crow's Feet Lines / Frown Lines / Glabellar Lines / Upper Facial Rhytides	1
3	Completed	Treatment	Crow's Feet Lines / Lateral Canthal Lines	1
3	Completed	Treatment	Crow's Feet Lines / Lateral Canthus Rhytides	2
3	Completed	Treatment	Disseminated Sclerosis / Neurogenic Bladder Dysfunction / Urinary Incontinence (UI)	1
3	Completed	Treatment	Disseminated Sclerosis / Tremors	1
3	Completed	Treatment	Essential Blepharospasm	1
3	Completed	Treatment	Facial Rhytides / Glabellar Rhytides	1
3	Completed	Treatment	Forehead Rhytides / Glabellar Rhytides	1
3	Completed	Treatment	Frown Lines Between the Eyebrows / Glabellar Rhytides	1
3	Completed	Treatment	Glabellar Frown Lines	1
3	Completed	Treatment	Glabellar Lines	3
3	Completed	Treatment	Glabellar Rhytides	2
3	Completed	Treatment	Hyperhidrosis	1
3	Completed	Treatment	Lateral Epicondylitis	1
3	Completed	Treatment	Lateral Periorbital Wrinkles	1
3	Completed	Treatment	Leg Spasticity	1
3	Completed	Treatment	Low Back Pain (LBP)	1
3	Completed	Treatment	Lower Extremity Deformities, Congenital / Unequal Length of Limbs; Congenital	1
3	Completed	Treatment	Lower Limb Spasticity Due to Cerebral Palsy	1
3	Completed	Treatment	Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy	1
3	Completed	Treatment	Migraine Disorders	3
3	Completed	Treatment	Moderate to Severe Glabellar Line	1
3	Completed	Treatment	Muscle Spasticity	1
3	Completed	Treatment	Myofascial Pain Syndromes	1
3	Completed	Treatment	Nervous System Disorders	2
3	Completed	Treatment	Neurogenic Detrusor Overactivity	1
3	Completed	Treatment	Notalgia Paresthetica	1
3	Completed	Treatment	Other Infantile Cerebral Palsy	1
3	Completed	Treatment	Over Active Bladder	5
3	Completed	Treatment	Over Active Bladder / Urinary Incontinence (UI)	2
3	Completed	Treatment	Post-stroke Spasticity of the Lower Limb	1
3	Completed	Treatment	Post-stroke Spasticity of the Upper Limb	1
3	Completed	Treatment	Post-stroke Upper Limb Spasticity	1
3	Completed	Treatment	Raynaud's Syndrome / Scleroderma	1
3	Completed	Treatment	Refractory Urge Urinary Incontinence / Urinary Incontinence, Urge	1
3	Completed	Treatment	Skin Aging	5
3	Completed	Treatment	Spasticity	1
3	Completed	Treatment	Spasticity Post-Traumatic Brain Injury / Spasticity, Post-Stroke	1
3	Completed	Treatment	Spasticity of the Upper and Lower Limb Due to Cerebral Causes	1
3	Completed	Treatment	Spasticity, Post-Stroke	1
3	Completed	Treatment	Spasticity / Strokes	2
3	Completed	Treatment	Strabismus	1
3	Completed	Treatment	Upper Limb Spasticity	1
3	Completed	Treatment	Facial fine wrinkling	1
3	Enrolling by Invitation	Treatment	Chronic Migraine	1
3	Enrolling by Invitation	Treatment	Over Active Bladder	1
3	Not Yet Recruiting	Treatment	Cerebrovascular Accidents	1
3	Not Yet Recruiting	Treatment	Obstetrical Brachial Plexus Palsy	1
3	Not Yet Recruiting	Treatment	Vulvodynia	1
3	Recruiting	Supportive Care	BRCA1 Mutations / BRCA2 Mutation / Breast Diseases / Cancer, Breast / Neoplasms / Postoperative pain	1
3	Recruiting	Treatment	COMPARISON BETWEEN GROUP TREATED WITH BOTULINUM TOXIN AND PLACEBO	1
3	Recruiting	Treatment	Cerebral Palsy (CP) / Chronic Troublesome Sialorrhea / Disability, Intellectual / Strokes / Traumatic Brain Injury (TBI)	1
3	Recruiting	Treatment	Cerebral Palsy (CP) / Muscle Spasticity / Pediatrics	2
3	Recruiting	Treatment	Cerebral Palsy (CP) / Muscle Spasticity / Pediatrics / Strokes	2
3	Recruiting	Treatment	Cerebrovascular Accidents	1
3	Recruiting	Treatment	Lateral Epicondylitis	1
3	Recruiting	Treatment	Over Active Bladder	1
3	Recruiting	Treatment	Over Active Bladder / Urinary Incontinence (UI)	2
3	Recruiting	Treatment	Strokes	2
3	Recruiting	Treatment	Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children	1
3	Recruiting	Treatment	Urinary Bladder, Overactive / Urinary Incontinence (UI)	1
3	Recruiting	Treatment	Urinary Incontinence (UI)	2
3	Recruiting	Treatment	Vestibulodynia	1
3	Terminated	Treatment	Chronic Post Traumatic Headache	1
3	Terminated	Treatment	Chronic Prostatitis With Chronic Pelvic Pain Syndrome / Prostatitis	1
3	Terminated	Treatment	Detrusor Hyperreflexia / Over Active Bladder / Urge Incontinence / Urinary Incontinence (UI) / Urinary Urge Incontinence	1
3	Terminated	Treatment	Detrusor Overactivity / Urge Urinary Incontinence / Urinary Incontinence (UI) / Urination urgency of	1
3	Terminated	Treatment	Lower Urinary Tract Discomfort / Stent Pain	1
3	Terminated	Treatment	Muscle Spasticity / Strokes	1
3	Terminated	Treatment	Over Active Bladder	1
3	Terminated	Treatment	Patellofemoral Pain Syndrome	1
3	Terminated	Treatment	Skin Aging	1
3	Unknown Status	Treatment	Hemiplegic Patients Post-AVC	1
3	Unknown Status	Treatment	Over Active Bladder	1
3	Unknown Status	Treatment	Scarring	1
3	Unknown Status	Treatment	Facial fine wrinkling	1
3	Withdrawn	Not Available	Neurocostal neuralgia / Pain Due to Certain Specified Procedures / Pain, Neuropathic	1
3	Withdrawn	Prevention	Migraine Disorders	2
3	Withdrawn	Treatment	Muscle Spasticity / Strokes	1
4	Active Not Recruiting	Prevention	Migraine Disorders	1
4	Active Not Recruiting	Treatment	Chronic Idiopathic Constipation / Functional Constipation	1
4	Active Not Recruiting	Treatment	Parkinson's Disease (PD)	1
4	Completed	Not Available	Healthy Subjects, Only With Wrinkles on Forehead	1
4	Completed	Not Available	Migraine Disorders	1
4	Completed	Not Available	Urinary Bladder, Overactive	1
4	Completed	Prevention	Strokes / Upper Limb Spasticity	1
4	Completed	Treatment	Aging	1
4	Completed	Treatment	Blepharospasm	1
4	Completed	Treatment	Brain Injury / Spasticity Secondary to Either a Disorder or Trauma / Spinal Cord Injuries (SCI) / Strokes / Tumors	1
4	Completed	Treatment	Brain Injury / Spasticity / Strokes	1
4	Completed	Treatment	Brow Ptosis	1
4	Completed	Treatment	Brow Ptosis / Lid Ptosis	1
4	Completed	Treatment	Cerebral Palsy (CP)	1
4	Completed	Treatment	Cerebral Palsy and Botulinum Toxin	1
4	Completed	Treatment	Cerebrovascular Accidents / Muscle Spasticity	2
4	Completed	Treatment	Cervical Dystonia	4
4	Completed	Treatment	Chronic Migraine	5
4	Completed	Treatment	Crow's Feet Lines / Facial Rhytides / Glabellar Lines / Nasolabial Folds	1
4	Completed	Treatment	Diabetic Polyneuropathies / Other Polyneuropathies / Postherpetic Neuralgia	1
4	Completed	Treatment	Disseminated Sclerosis / Muscle Spasticity	1
4	Completed	Treatment	Esotropia / Exotropia	1
4	Completed	Treatment	Essential Blepharospasm	1
4	Completed	Treatment	Facial Asymmetry / Facial Nerve Injuries / Facial Paresis Associated With Facial Nerve Dysfunction / Synkinesis	1
4	Completed	Treatment	Facial Rhytides	1
4	Completed	Treatment	Glabellar Frown Lines	3
4	Completed	Treatment	Glabellar Furrows	1
4	Completed	Treatment	Glabellar Lines	1
4	Completed	Treatment	Glabellar Rhytides	1
4	Completed	Treatment	Hallux Valgus	1
4	Completed	Treatment	Hyperhidrosis	2
4	Completed	Treatment	Interstitial Cystitis / Painful Bladder Syndrome (PBS)	1
4	Completed	Treatment	Intrinsic Aging of Skin / Solar Elastosis	1
4	Completed	Treatment	Migraine Disorders	2
4	Completed	Treatment	Mild to Moderate Temporal Atrophy / Moderate to Severe Glabellar Rhytids / Moderate to Severe Periorbital Rhytids	1
4	Completed	Treatment	Muscle Spasticity	1
4	Completed	Treatment	Over Active Bladder	1
4	Completed	Treatment	Over Active Bladder / Urinary Incontinence (UI)	1
4	Completed	Treatment	Pain, Neuropathic / Spinal Cord Injuries (SCI)	1
4	Completed	Treatment	Plantar Fascitis	1
4	Completed	Treatment	Skin Aging	1
4	Completed	Treatment	Spasmodic Torticollis	1
4	Completed	Treatment	Spasticity	1
4	Completed	Treatment	Sun-induced Wrinkles	1
4	Completed	Treatment	Torticollis	1
4	Completed	Treatment	Upper Limb Spasticity	1
4	Completed	Treatment	Wrinkles in Frontal Area	1
4	Completed	Treatment	Facial fine wrinkling	1
4	Enrolling by Invitation	Prevention	Over Active Bladder / Painful Bladder Syndrome (PBS) / Urinary Bladder, Neurogenic / Urinary Urge Incontinence	1
4	Not Yet Recruiting	Treatment	Activity / Pain	1
4	Recruiting	Not Available	Crow's Feet Lines / Lateral Canthal Lines	1
4	Recruiting	Prevention	Other Degenerative Disorders of Eyelid and Periocular Area	1
4	Recruiting	Treatment	Anxiety Disorder Social / Feeling Anxious	1
4	Recruiting	Treatment	Breast Diseases / Neoplasms / Neoplasms by Site / Neoplasms, Breast / Skin Diseases	1
4	Recruiting	Treatment	Brow Lifting	1
4	Recruiting	Treatment	Cerebral Palsy (CP) / Muscle Spasticity	1
4	Recruiting	Treatment	Interstitial Cystitis	1
4	Recruiting	Treatment	Mixed Urinary Incontinence / Stress Urinary Incontinence (SUI) / Urgency Incontinence	1
4	Recruiting	Treatment	Osteoarthritis of the Knees	1
4	Recruiting	Treatment	Spastic Hemiplegia	1
4	Recruiting	Treatment	Spinal Cord Injuries (SCI) / Urinary Bladder, Overactive	1
4	Recruiting	Treatment	Stroke Rehabilitation / Stroke Rehabilitation Spasticity Management	1
4	Recruiting	Treatment	Urinary Bladder, Overactive / Urinary Incontinence (UI)	1
4	Terminated	Treatment	Arthritis Multiple Joint / Basal Thumb Joint Arthritis / Basilar Joint Arthritis / Carpometacarpal Arthritis / Trapeziometacarpal Arthritis	1
4	Terminated	Treatment	Chronic Male Pelvic Pain Syndrome	1
4	Terminated	Treatment	Low Back Pain (LBP)	1
4	Terminated	Treatment	Parkinson's Disease (PD)	1
4	Terminated	Treatment	Spasmodic Torticollis	1
4	Unknown Status	Prevention	Autonomic Dysreflexia	1
4	Unknown Status	Treatment	Bruxism	1
4	Unknown Status	Treatment	Catocholamine Induced Finger Necrosis	1
4	Unknown Status	Treatment	Chronic Low Back Pain (CLBP)	1
4	Unknown Status	Treatment	Elastosis Senilis / Skin Aging	1
4	Unknown Status	Treatment	Major Depressive Disorder (MDD)	1
4	Unknown Status	Treatment	Muscle Spasticity	1
4	Unknown Status	Treatment	Overactive Detrusor	1
4	Unknown Status	Treatment	Scarring	1
4	Unknown Status	Treatment	Sleep Bruxism	1
4	Withdrawn	Treatment	Foot Deformities / Leg Length Inequality	1
4	Withdrawn	Treatment	Graves Ophthalmopathy	1
Not Available	Active Not Recruiting	Not Available	Detrusor, Overactive / Disseminated Sclerosis / Lower Urinary Tract Symptoms (LUTS) / Neurogenic Bladder Dysfunction / Urge Incontinence	1
Not Available	Active Not Recruiting	Not Available	Lower Limb Spasticity	1
Not Available	Active Not Recruiting	Not Available	Muscle Spasticity	1
Not Available	Active Not Recruiting	Not Available	Over Active Bladder / Urinary Incontinence (UI)	1
Not Available	Active Not Recruiting	Treatment	Facial Flushing	1
Not Available	Active Not Recruiting	Treatment	Headaches	1
Not Available	Active Not Recruiting	Treatment	Idiopathic Clubfoot (Talipes Equinovarus)	2
Not Available	Active Not Recruiting	Treatment	Facial fine wrinkling	1
Not Available	Completed	Not Available	Blepharospasm / Cervical Dystonia	1
Not Available	Completed	Not Available	Chronic Migraine, Headaches	1
Not Available	Completed	Not Available	Facial Rhytides	1
Not Available	Completed	Not Available	Glabellar Lines	1
Not Available	Completed	Not Available	Glabellar Lines / Hyperhidrosis / Muscle Spasticity	1
Not Available	Completed	Not Available	Headaches / Migraine Disorders	1
Not Available	Completed	Not Available	Migraine Disorders	1
Not Available	Completed	Not Available	Mumps	1
Not Available	Completed	Not Available	Muscle Spasticity	1
Not Available	Completed	Not Available	Skin Laxity	1
Not Available	Completed	Not Available	Spasticity, Post-Stroke	1
Not Available	Completed	Not Available	Torticollis	1
Not Available	Completed	Not Available	Urinary Bladder, Neurogenic / Urinary Bladder, Overactive	1
Not Available	Completed	Not Available	Urinary Bladder, Overactive / Urinary Incontinence (UI)	2
Not Available	Completed	Not Available	Urinary Incontinence (UI)	1
Not Available	Completed	Diagnostic	Botulinum Toxins, Type A / Normal, Healthy Volunteers / Strength, Muscle	1
Not Available	Completed	Health Services Research	Healthy Volunteers	1
Not Available	Completed	Health Services Research	Muscle Spasticity / Strokes	1
Not Available	Completed	Prevention	Herpes Labialis	1
Not Available	Completed	Prevention	Post Traumatic Stiffness	1
Not Available	Completed	Supportive Care	Pain	1
Not Available	Completed	Treatment	Achalasia, Esophageal	1
Not Available	Completed	Treatment	Axillary Hyperhidrosis	1
Not Available	Completed	Treatment	Cerebral Palsy (CP) / Muscle Spasticity	1
Not Available	Completed	Treatment	Diabetes Mellitus (DM) / Pain, Neuropathic	1
Not Available	Completed	Treatment	Diabetes Mellitus (DM) / Peripheral Neuropathy / Plantar Ulcers	1
Not Available	Completed	Treatment	Epicondylitis, Lateral Humeral / Lateral Epicondylitis	1
Not Available	Completed	Treatment	Facial Paralysis	1
Not Available	Completed	Treatment	Facial Rhytides / Glabellar Frown Lines	1
Not Available	Completed	Treatment	Facial Wrinkles	1
Not Available	Completed	Treatment	HIV Posterior Cheek Enlargement	1
Not Available	Completed	Treatment	Hyperhidrosis	1
Not Available	Completed	Treatment	Keratoconus	1
Not Available	Completed	Treatment	Non-neurogenic / Urinary Urge Incontinence	1
Not Available	Completed	Treatment	Post-stroke Shoulder Pain and Spasticity	1
Not Available	Completed	Treatment	Primary Axillary Hyperhidrosis	1
Not Available	Completed	Treatment	Raynaud's Syndrome	1
Not Available	Completed	Treatment	Skin Wrinklings	1
Not Available	Completed	Treatment	Spastic Equinovarus	1
Not Available	Completed	Treatment	Subacute Cervical Pain / Subacute Upper Back Pain	1
Not Available	Completed	Treatment	Tremor, Essential	1
Not Available	Completed	Treatment	Urinary Incontinence (UI)	1
Not Available	Completed	Treatment	Vaginismus	1
Not Available	Enrolling by Invitation	Not Available	Unilateral Spastic Cerebral Palsy	1
Not Available	Recruiting	Not Available	Esthetic Outcome of Injection of Botulinum Toxin Type-A in Cleft Lip Repair	1
Not Available	Recruiting	Not Available	Lower Limb Spasticity	1
Not Available	Recruiting	Not Available	Mixed Incontinence, Urge and Stress	1
Not Available	Recruiting	Not Available	Urinary Bladder, Overactive	1
Not Available	Recruiting	Treatment	Chronic Vocal Tic / Gilles de la Tourette's Syndrome	1
Not Available	Recruiting	Treatment	Epicondylitis, Lateral Humeral / Lateral Epicondylitis	1
Not Available	Recruiting	Treatment	Migrainous Headache	1
Not Available	Recruiting	Treatment	Myofascial Pelvic Pain	1
Not Available	Recruiting	Treatment	Pelvic Pain	1
Not Available	Recruiting	Treatment	Plantar fascial fibromatosis	1
Not Available	Suspended	Treatment	Pain	1
Not Available	Terminated	Not Available	Cerebral Palsy (CP)	1
Not Available	Terminated	Treatment	Brain Injury / Stiff Knee Gait	1
Not Available	Terminated	Treatment	Equinus Contracture	1
Not Available	Terminated	Treatment	Migrainous Headache	1
Not Available	Terminated	Treatment	Transient ischemia attacks / Vasopressor	1
Not Available	Unknown Status	Treatment	Alopecia Areata (AA)	1
Not Available	Unknown Status	Treatment	Esophageal Spasm, Diffuse	1
Not Available	Unknown Status	Treatment	Flexion Contracture Following Total Knee Replacement	1
Not Available	Unknown Status	Treatment	Lateral Epicondylitis / Type A Botulinum Toxin	1
Not Available	Unknown Status	Treatment	Pain	1
Not Available	Withdrawn	Not Available	Chronic Migraine, Headaches	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Dosage forms

Form	Route	Strength
Injection, powder, lyophilized, for solution	Intradermal; Intramuscular	100 [USP'U]/1
Injection, powder, lyophilized, for solution	Intradermal; Intramuscular	200 [USP'U]/1
Powder, for solution	Intramuscular	100 unit
Injection, powder, lyophilized, for solution	Intramuscular	300 U/1
Injection, powder, lyophilized, for solution	Intramuscular	500 U/1
Powder, for solution	Intramuscular	300 unit
Powder, for solution	Intramuscular	500 unit
Injection, powder, lyophilized, for solution	Intramuscular	100 [USP'U]/1
Injection, powder, lyophilized, for solution	Intramuscular	200 [USP'U]/1
Injection, powder, lyophilized, for solution	Intramuscular	50 [USP'U]/1
Powder, for solution	Intramuscular	50 unit

Prices

Unit description	Cost	Unit
Botox 200 unit vial	1260.0USD	vial
Dysport 500 unit vial	852.0USD	vial
Botox 100 unit	655.2USD	vial
Botox 100 unit vial	630.0USD	vial
Botox cosmetic 100 unit vial	630.0USD	vial
Botox cosmetic 50 unit vial	346.8USD	vial
Botox (100 - 200 unit/Vial)	3.74USD	vial

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
CA2280565	No	2005-11-15	2019-08-20	Canada
CA2310845	No	2001-05-15	2014-06-07	Canada

Properties

State

Solid

Experimental Properties

Property	Value	Source
water solubility	Soluble	Not Available
hydrophobicity	-0.368	Not Available
isoelectric point	6.06	Not Available

Taxonomy

Description

Not Available

Kingdom

Organic Compounds

Super Class

Organic Acids

Class

Carboxylic Acids and Derivatives

Sub Class

Amino Acids, Peptides, and Analogues

Direct Parent

Peptides

Alternative Parents

Not Available

Substituents

Not Available

Molecular Framework

Not Available

External Descriptors

Not Available

Targets

Details

1. Synaptosomal-associated protein 25

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Syntaxin-1 binding
Specific Function:: t-SNARE involved in the molecular regulation of neurotransmitter release. May play an important role in the synaptic function of specific neuronal systems. Associates with proteins involved in vesicle docking and membrane fusion. Regulates plasma membrane recycling through its interaction with CENPF. Modulates the gating characteristics of the delayed rectifier voltage-dependent potassium chann...
Gene Name:: SNAP25
Uniprot ID:: P60880
Molecular Weight:: 23314.905 Da

References

Zhou JY, Wang ZF, Ren XM, Tang MZ, Shi YL: Antagonism of botulinum toxin type A-induced cleavage of SNAP-25 in rat cerebral synaptosome by toosendanin. FEBS Lett. 2003 Dec 4;555(2):375-9. [PubMed:14644446 ]
Flynn TC: Myobloc. Dermatol Clin. 2004 Apr;22(2):207-11, vii. [PubMed:15222581 ]
Okada M, Yoshida S, Zhu G, Kaneko S: [Methodological consideration in studying the exocytosis mechanisms using microdialysis]. Nihon Shinkei Seishin Yakurigaku Zasshi. 2004 Aug;24(4):165-70. [PubMed:15484814 ]
Frassoni C, Inverardi F, Coco S, Ortino B, Grumelli C, Pozzi D, Verderio C, Matteoli M: Analysis of SNAP-25 immunoreactivity in hippocampal inhibitory neurons during development in culture and in situ. Neuroscience. 2005;131(4):813-23. [PubMed:15749336 ]
Straughan D: Progress in applying the Three Rs to the potency testing of Botulinum toxin type A. Altern Lab Anim. 2006 Jun;34(3):305-13. [PubMed:16831062 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Details

2. Rho-related GTP-binding protein RhoB

Kind: Protein
Organism: Human
Pharmacological action: unknown

General Function:: Gtpase activity
Specific Function:: Mediates apoptosis in neoplastically transformed cells after DNA damage. Not essential for development but affects cell adhesion and growth factor signaling in transformed cells. Plays a negative role in tumorigenesis as deletion causes tumor formation. Involved in intracellular protein trafficking of a number of proteins. Targets PKN1 to endosomes and is involved in trafficking of the EGF rece...
Gene Name:: RHOB
Uniprot ID:: P62745
Molecular Weight:: 22123.185 Da

References

Ishida H, Zhang X, Erickson K, Ray P: Botulinum toxin type A targets RhoB to inhibit lysophosphatidic acid-stimulated actin reorganization and acetylcholine release in nerve growth factor-treated PC12 cells. J Pharmacol Exp Ther. 2004 Sep;310(3):881-9. Epub 2004 May 12. [PubMed:15140914 ]

Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23

Get DrugBank to go!

Targets

References

References